國家衛生研究院 NHRI:Item 3990099045/8600
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12189/12972 (94%)
造访人次 : 955235      在线人数 : 632
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/8600


    题名: DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study
    作者: Shiao, HY;Hsu, TAJ;Chen, CT;Yeh, TK;Hsieh, HP
    贡献者: Institute of Biotechnology and Pharmaceutical Research
    摘要: Lung cancer is the major cause of cancer death in the world while non small cell lung cancer (NSCLC) accounts approximately 85% of all lung cancer diagnosis. EGFR mutations, found in 10–30% of patients with NSCLC characterize a subpopulation with exquisite sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, the clinical benefits of first-generation TKIs (like gefitinib or erlotinib) can be further improved because of the development of drug-acquired resistance within 10–14 months in patients who initially respond to the treatment. Therefore, there is a need to discover next generation medicines as EGFR-TKIs for NSCLC patients. Our EGFR program was first started to screen 20,000 in-house compounds for EGFRWT activity in EGFR-transfected 32D cells and further performed knowledge-based design. We had identified DBPR112 as a potent EGFR-TKI with oralin vivo activity in a mouse model for lung adenocarcinoma. DBPR112 showed IC50 of 2 nM in HCC827 cells and potent EGFRWT (IC50: 10 nM) and EGFRL858R/T790M (IC50: 50 nM) kinase inhibition which are better than gefitinib. DBPR112 was orally (F = 49%) administered against the growth of human lung HCC827 tumors subcutaneously xenografted in nude mice. A dramatic reduction of the tumor size was noted in the tumors treated with DBPR112 without significant loss of body weights in the nude mice. Considering the fact that EGFR kinase plays an important role in lung adenocarcinoma, our goal is to develop novel and potent EGFR kinase inhibitors for the treatment of lung cancer, either as a single agent or in combination with existing cancer treatment. DBPR112 is a highly potent small-molecule against various forms of EGFR kinase. The non-clinical profile of DBPR112 showed promising in vivo efficacy. We, therefore, propose to design a preclinical program to assess the developability of DBPR112 and conduct comprehensive preclinical studies. We hope to make DBPR112 an investigational new drug for the treatment of lung cancer in the near future.
    日期: 2014-03
    關聯: Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI.
    Link to: http://acselb-529643017.us-west-2.elb.amazonaws.com/chem/247nm/program/view.php
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000348457602470
    显示于类别:[徐祖安] 會議論文/會議摘要
    [陳炯東] 會議論文/會議摘要
    [葉燈光] 會議論文/會議摘要
    [謝興邦] 會議論文/會議摘要

    文件中的档案:

    没有与此文件相关的档案.



    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈